Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.<\/p>\n
The USD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market has been analyzed across the following segments: <\/p>\n
Key therapeutic areas<\/p>\n
Type of vector<\/p>\n
Type of therapy<\/p>\n
Type of gene modification<\/p>\n
Route of administration<\/p>\n
Key geographical regions <\/p>\n
For more information, please visit https:\/\/www.rootsanalysis.com\/reports\/view_document\/gene-therapy-market-3rd-edition-2019-2030\/268.html<\/a><\/p>\n The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:<\/p>\n Table of Contents<\/p>\n<\/p>\n For more information, please click on the following link: <\/p>\n https:\/\/www.rootsanalysis.com\/reports\/view_document\/gene-therapy-market-3rd-edition-2019-2030\/268.html<\/a> <\/p>\n About Roots Analysis<\/p>\n Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]<\/p>\n Contact Information<\/p>\n Roots Analysis Private Limited<\/p>\n Gaurav Chaudhary<\/p>\n +1 (415) 800 3415<\/p>\n [emailprotected]<\/p>\n <\/p>\n Read more: <\/p>\n Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030 - Market Research Posts<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Continue reading